Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®

NCT01477333 is registered in ClinicalTrials.gov with United Therapeutics as lead sponsor.

NCT NCT01477333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01477333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of the Safety and Efficacy of the Addition of UT-15C SR to Pulmonary Arterial Hypertension Patients Currently Receiving Tyvaso®
Lead sponsor
United Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2011
Completion date
November 30, 2013
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension